William Goebel

William Goebel is a director of quality at CimQuest Inc.

Articles

November 1st 2003

FDA's revised guidance on 21 CFR Part 11 offers relief to the regulated industry by providing for enforcement discretion and suggesting a risk-based approach to compliance.

Latest Updated Articles

Published: October 11th 2024 | Updated: October 18th 2024

Buy, Sell, Hold: Cell and Gene Therapy - Part 1

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com

Published: September 10th 2024 | Updated: September 18th 2024

CPHI Milan Announces 2024 CPHI Pharma Award Finalists

Published: August 21st 2024 | Updated: December 28th 2024

Pharmaceutical Technology Editorial Advisory Board

Published: November 25th 2024 | Updated: December 28th 2024

Leveraging Integrated Patient-Centric Innovations When Developing Today’s Biologics

Published: December 20th 2024 | Updated: December 28th 2024

Drug Digest: Challenges and Triumphs in Next-Generation Biotherapeutic Development

Published: February 23rd 2024 | Updated: December 28th 2024

Europa Perspectives: Helping to Navigate the Regulatory System

About Us

Advertise

Editorial Info

Editorial Advisory Board

Do Not Sell My Personal Information

Terms and Conditions

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777